Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial

Xu, Xiangru; Zhou, Shuang; Chen, Caiyu; Li, Jinhua; Wu, Hongze; Jin, Guoqiang; Zhou, Jing; Wang, Gang; Cao, Min; Sun, Ding; Zhang, Wen; Peng, Wei; Pu, Yuting; Sun, Yuting; Fang, Bangjiang; Xu, Jian‐Guang

doi:10.1016/j.phymed.2022.154514

Cited by 9 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] However, facing the large-scale outbreak of COVID-19 in Shanghai, most studies have focused on the epidemiological and clinical characteristics of infected patients as well as the genomic signature of the virus and clinical interventions. [18][19][20][21] Few studies focused on the mental health status of infected patients. Therefore, this study aimed to analyze the mental health status of patients infected with the SARS-CoV-2 Omicron Variant in Shanghai and its relationship with clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study investigating the anxiety and depression level of novel coronavirus Omicron patients in 2022

Zhang

et al. 2022

Medicine

Self Cite

View full text Add to dashboard Cite

Introduction: The novel coronavirus disease 2019 continues to spread widely, not only causing physical disorders in patients but also impairing mental health, bringing a heavy burden on global public health. This study aimed to evaluate the anxiety and depression status of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant in Shanghai. Methods/design: This study aimed to retrospectively analyze 2000 patients infected with the SARS-CoV-2 Omicron variant. Data from patients assessed with demographic information, anxiety and depressive symptoms were collected using a questionnaire. Clinical and laboratory data were collected using electronic medical system. Anxiety and depression were assessed using the Self-Rating Anxiety Scale, the Generalized Anxiety Disorder Scale, and the Patient Health Questionnaire. Clinical information and laboratory indicators included age, sex, blood pressure, blood glucose, basic disease, time of diagnosis onset, duration of hospitalization, vaccination status of novel coronavirus disease 2019, and virus-negative conversion time. Discussion: This study will provide evidence-based suggestions for early psychological intervention in patients infected with the SARS-CoV-2 Omicron Variant.

show abstract

Section: Discussionmentioning

confidence: 99%

A retrospective study investigating the anxiety and depression level of novel coronavirus Omicron patients in 2022

Zhang

et al. 2022

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Azvudine is effective in clinically mild and severe patients, and the virus clearance time is approximately 5 days [95]. In recent a prospective, open-label, randomized controlled trial (ChiCTR2 200060292), Xu et al [96] demonstrated that treatment with Reyanning (RYN) mixture accelerated virus clearance and promoted disease recovery in patients with asymptomatic and mild Omicron infections, and disease progression or serious adverse events were not observed. Pavan et al [97] analysed the structural features of the S protein and Main Protease (Mpro) of XE, XD, and XF, and proposed the development of pan-coronaviral drugs that could prevent future coronavirus-associated pandemics.…”

Section: Current Therapeutics Against Covid-19mentioning

confidence: 99%

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages

et al. 2023

View full text Add to dashboard Cite

The SARS-CoV-2 Omicron is currently the predominant circulating variant in the COVID-19 pandemic. The dominating Omicron sublineages respond to host immune pressure and develop advantageous mutations or genetic recombination, which result in variants that are more contagious or better at escaping immune responses in response to previous infection or vaccination. Meanwhile, multiple genetic recombination events have been reported in coinfection cases, the majority of which have resulted from the recombination between co-circulating Omicron BA.1 (or BA.1.1) and Delta variant or BA.2. Here, we review the knowledge and characterization of recombination for SARS-CoV-2 at the population level, provide an update on the occurrence of newly circulating Omicron sublineages, and discuss the effectiveness of novel vaccines/therapeutic drugs against the Omicron variant.

show abstract

“…The China Food and Drug Administration (CFDA) has approved Xuebijing for treating new coronavirus pneumonia with severe and critical systemic inflammatory response syndrome or/and multiple organ failure, and Lianhua Qingwen for treating fever, cough, and fatigue caused by the light and ordinary types of the new coronavirus pneumonia [ 29 , 30 ]; each TCM formulation consists of several active ingredients with multitarget effects that are intended to counteract drug resistance. In particular, two TCM formulations (the Reyanning mixture and Jingyin granules) have shown potent anti-inflammatory and immunomodulatory effects [ 31 , 32 ]. China is now conducting many clinical trials assessing the effectiveness of various TCM formulations for the treatment of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19

Lin

Huang

2023

J Biomed Sci

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has impacted human lifestyles around the world, causing huge distress in terms of public health systems, emergency response capacity and economic development. The causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with respiratory involvement, cardiovascular-related diseases, and ultimately causes multiple organ failure and death in severely affected individuals. Thus, effective prevention or early treatment of COVID-19 is critical. An effective vaccine offers a way out of the pandemic for governments, the scientific community and people worldwide, but we still lack effective drug therapies, including treatments for the prevention and treatment of COVID-19. This had led to a high global demand for many complementary and alternative medicines (CAMs). Moreover, many healthcare providers are now requesting information about CAMs that prevent, relieve, or treat the symptoms of COVID-19 and even alleviate vaccine-related side effects. Experts and scholars must therefore become familiar with the use of CAMs in COVID-19, current research directions and effectiveness of CAMs for COVID-19. This narrative review updates the current status and research worldwide on the use of CAMs for COVID-19. The review provides reliable evidence on theoretical viewpoints and therapeutic efficacies of CAM combinations, and evidence in support of the therapeutic strategy of Taiwan Chingguan Erhau (NRICM102) against moderate-to-severe novel coronavirus infectious disease in Taiwan.

show abstract

Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial

Cited by 9 publications

References 21 publications

A retrospective study investigating the anxiety and depression level of novel coronavirus Omicron patients in 2022

A retrospective study investigating the anxiety and depression level of novel coronavirus Omicron patients in 2022

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages

Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19

Contact Info

Product

Resources

About